Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panobinostat in Low/Int-1 Risk MDS (GEPARD)
NCT01034657Phase 2Terminated
- Sponsor
- Novartis
- Start
- Nov 2009
- Primary completion
- Aug 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of panobinostat in myelodysplastic syndrome (MDS), sponsored by Novartis. Started Nov 2009; status: terminated.
02
Drugs
panobinostat
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT01034657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01034657.